Become a Member
  • Track your favourite stocks
  • Create & monitor portfolios
  • Daily portfolio value
Sign Up
Quickpicks
Add shares to your
quickpicks to
display them here!

Reorganistion of share options

10th Feb 2011 12:12

RNS Number : 0248B
3D Diagnostic Imaging PLC
10 February 2011
 



 

 

For immediate release

10 February 2011

 

 

3D DIAGNOSTIC IMAGING PLC

("3D" or "the Company")

 

Director's Dealings - Reorganisation of Share Options

 

As detailed in the admission document dated 26 October 2010 ("the Admission Document"), the Company has both an unapproved Share Option Scheme and an EMI Share Option Scheme.

 

As disclosed in the Admission Document, Graham Lay and Oliver Cooke, have options over 8,523,741 and 5,966,618 ordinary shares respectively that had been issued to them under the unapproved Share Option Scheme. The Company was informed on 12 January 2011 that these options have now been cancelled and replaced with options over 1,766,649 and 1,999,983 ordinary shares respectively issued under the EMI Share Option Scheme and with options over 6,757,092 and 3,966,635 ordinary shares respectively issued under the unapproved Share Option Scheme.

 

As a consequence of this reorganisation there has been no change to the aggregate number, the exercise price, the vesting terms or to the performance criteria of the options held by either Graham Lay or Oliver Cooke.

 

Following this transaction there is no change to the beneficial holdings of Graham Lay or Oliver Cooke in the Company.

 

 

 

For further information please contact:

 

3D Diagnostic Imaging Plc

Graham Lay, CEO

+44 (0) 1624 679000

Oliver Cooke, FD

finnCap

 NOMAD & Broker

Geoff Nash

Henrik Persson

 

+44 (0)20 7600 1658

 

Buchanan Communications

Financial PR

Diane Stewart

Carrie Clement

+44 (0) 207 466 5000

 

 

 

Notes to Editors:

 

CarieScan PROtm

 

The PROtm is a highly accurate, easy to use, hand held device for the early detection and monitoring of dental caries (tooth decay). The PROtm already has CE Mark and FDA 510K approval for sale in Europe and the USA.

 

The CarieScan PROtm measures the presence of tooth decay earlier and more accurately than any other device on the market and is more than 90% accurate in detecting both sound and carious teeth, well ahead of other methods. It detects "hidden" decay, providing dental practitioners with the opportunity to arrest or even reverse decay, driving the trend towards preventative dental care.

 

The lightweight caries detection monitor not only offers best-in-class performance for decay detection but also allows easy monitoring of the effect of treatment regimes to show decay advancement or regression, thus enabling dentists to tailor treatment to the needs of the patient at a low cost. The CarieScan PROtm consists of a hand piece and a disposable sensor which is held against the tooth being examined in a process which takes approximately 4 seconds per tooth with the result displayed on the CarieScan PROtm.

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
RDSTMMTTMBMBBLB

Related Shares:

Afriag Global
FTSE 100 Latest
Value8,275.66
Change0.00